Lv3
210 积分 2025-07-05 加入
64414 Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT
6天前
已关闭
Short‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and NMA
6天前
已完结
APOS therapy improves clinical measurements and gait in patients with knee osteoarthritis
25天前
已完结
Alterations in Sagittal Plane Knee Kinetics in Knee Osteoarthritis Using a Biomechanical Therapy Device
25天前
已完结
与附着点炎相关关节炎研究进展
1个月前
已完结
AB1733 LONG-TERM FOLLOW-UP AND RESULTS OF CHILDHOOD-ONSET ENTHESITIS-RELATED ARTHRITIS AND POLYARTHRITIS: HUR-BIO EXPERIENCE
1个月前
已关闭
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity
1个月前
已完结
Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions
2个月前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2个月前
已完结
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns
3个月前
已完结
皖公网安备34019202002308
